Cochrane · systematic review · CD006009
Dopamine agonists for the treatment of restless legs syndrome
Scholz, H, Trenkwalder, C, Kohnen, R, et al. · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
22
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 9.1%Moderate 11 · 50%High 9 · 40.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: dopamine agonists versus placebo
Population: patients with restless legs syndrome according to IRLSSG, 18 years or older
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IRLS Summary of findings: dopamine agonists vs placebo | no estimate extracted | 30 studies · 6380 participants | Moderate |
Periodic limb movements in sleep (PLMS Index) PLMS per hour of sleep (8 trials) or time in bed (7 trials) Summary of findings: dopamine agonists vs placebo | no estimate extracted | 15 studies · 1141 participants | Moderate |
Sleep efficiency Percentage of total sleep time per time in bed Summary of findings: dopamine agonists vs placebo | no estimate extracted | 11 studies · 677 participants | High |
Number of dropouts due to adverse events Summary of findings: dopamine agonists vs placebo | OR 1.82 [1.35, 2.45] | 34 studies · 7054 participants | High |
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse Summary of findings: dopamine agonists vs placebo | RR 1.44 [1.34, 1.54] | 27 studies · 6338 participants | High |
Subjective quality of sleep SMD on questionnaires MOS, RLS‐6, PSQI, VAS Summary of findings: dopamine agonists vs placebo | no estimate extracted | 22 studies · 4592 participants | High |
Quality of life SMD on 2 RLS‐QoL questionnaires Summary of findings: dopamine agonists vs placebo | no estimate extracted | 17 studies · 4312 participants | Moderate |
Summary of findings: dopamine agonists versus levodopa
Population: patients with restless legs syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IRLS Summary of findings: dopamine agonists vs levodopa | no estimate extracted | 2 studies · 383 participants | Moderate |
Periodic limb movements per hour of time in bed Summary of findings: dopamine agonists vs levodopa | no estimate extracted | 1 study · 39 participants | Low |
Number of drop outs due to adverse events Summary of findings: dopamine agonists vs levodopa | OR 1.7 | 3 studies · 504 participants | Moderate |
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse Summary of findings: dopamine agonists vs levodopa | RR 1.19 [0.91, 1.56] | 2 studies · 422 participants | Moderate |
Subjective quality of sleep RLS‐6; scale satisfaction with sleep: 0 to 10 (= low satisfaction) Summary of findings: dopamine agonists vs levodopa | no estimate extracted | 1 study · 344 participants | Low |
Quality of life RLS‐QoL: 0 to 60 (= severe impairment) Summary of findings: dopamine agonists vs levodopa | no estimate extracted | 1 study · 314 participants | Moderate |
Number of patients experiencing adverse events Summary of findings: dopamine agonists vs levodopa | OR 2.87 [0.43, 19] | 3 studies · 461 participants | Moderate |
Summary of findings: subgroups of dopamine agonists on IRLS
Population: patients with restless legs syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IRLS all dopamine agonists | no estimate extracted | 30 studies · 6380 participants | Moderate |
IRLS cabergoline | no estimate extracted | 2 studies · 127 participants | High |
IRLS lisuride | no estimate extracted | 2 studies · 378 participants | High |
IRLS pergolide | no estimate extracted | 1 study · 97 participants | High |
IRLS pramipexole | no estimate extracted | 8 studies · 2256 participants | Moderate |
IRLS ropinirole | no estimate extracted | 11 studies · 2301 participants | Moderate |
IRLS rotigotine | no estimate extracted | 5 studies · 958 participants | High |
IRLS sumanirole | no estimate extracted | 1 study · 263 participants | High |